Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
31.41
+0.73 (2.38%)
At close: Oct 23, 2026, 4:00 PM EDT
31.25
-0.16 (-0.51%)
After-hours: Oct 23, 2026, 7:30 PM EDT
Pharvaris Employees
Pharvaris had 148 employees as of June 30, 2026. The number of employees increased by 34 or 29.82% compared to the same quarter last year. That makes Pharvaris the 28,976th largest employer in the world and 3,680th in the United States.
Employees
148
Change (1Y)
34
Growth (1Y)
29.82%
Revenue / Employee
n/a
Profits / Employee
-$1,319,403
Market Cap
2.21B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 148 | 34 | 29.82% |
| Mar 31, 2026 | 134 | 15 | 12.61% |
| Dec 31, 2025 | 129 | 21 | 19.44% |
| Sep 30, 2025 | 118 | 26 | 28.26% |
| Jun 30, 2025 | 114 | 31 | 37.35% |
| Mar 31, 2025 | 119 | 36 | 43.37% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Sep 30, 2024 | 92 | 22 | 31.43% |
| Jun 30, 2024 | 83 | 15 | 22.06% |
| Mar 31, 2024 | 83 | 17 | 25.76% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Sep 30, 2023 | 70 | 14 | 25.00% |
| Jun 30, 2023 | 68 | 21 | 44.68% |
| Mar 31, 2023 | 66 | 25 | 60.98% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Sep 30, 2022 | 56 | 39 | 229.41% |
| Jun 30, 2022 | 47 | 30 | 176.47% |
| Mar 31, 2022 | 41 | 27 | 192.86% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Beam Therapeutics | 540 |
| Vericel | 398 |
| Biohaven | 274 |
| Celldex Therapeutics | 198 |
| Precigen | 160 |
PHVS News
- 2 days ago - Pharvaris upgraded to Buy at BofA after ‘valuation reset’ - TheFly
- 2 days ago - Pharvaris upgraded to Buy from Neutral at BofA - TheFly
- 16 days ago - Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial - TheFly
- 16 days ago - Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet - GlobeNewsWire
- 20 days ago - Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy - GlobeNewsWire
- 5 weeks ago - Pharvaris Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Pharvaris Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Pharvaris Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts